Human psychobiology of MDMA or 'Ecstasy': An overview of 25 years of empirical research

Human Psychopharmacology

Volumn 28, Issue 4, 2013, Pages 289-307

  Parrott, Andrew C ^a,b  

^a SWANSEA UNIVERSITY   (United Kingdom)

^b SWINBURNE UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Ecstasy; MDMA; memory; neurotoxicity; serotonin; SERT

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMPHETAMINE; COCAINE; DIAMORPHINE; HYDROCORTISONE; PLACEBO; SEROTONIN TRANSPORTER;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BODY TEMPERATURE; BRAIN CORTEX; BRAIN FUNCTION; COGNITION; CONFERENCE PAPER; EUPHORIA; HUMAN; HYDROCORTISONE BLOOD LEVEL; INTELLIGENCE; LEARNING; MEDICAL RESEARCH; MEMORY DISORDER; MOOD; NEUROCHEMISTRY; NEUROIMAGING; NEUROTOXICITY; NONHUMAN; PAIN; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PROBLEM SOLVING; PROSPECTIVE MEMORY; PROTEIN CONTENT; PROTEIN LOCALIZATION; PSYCHOBIOLOGY; PSYCHOMOTOR DISORDER; PSYCHOPHARMACOTHERAPY; REM SLEEP; RETROSPECTIVE MEMORY; SEROTONINERGIC SYSTEM; SLEEP DISORDER; SLEEP DISORDERED BREATHING; TEMPERATURE STRESS; VISION;

ECSTASY; MDMA; MEMORY; NEUROTOXICITY; SEROTONIN; SERT;

ANIMALS; APOPTOSIS; EMPIRICAL RESEARCH; HALLUCINOGENS; HUMANS; MEMORY DISORDERS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PSYCHOLOGY; STREET DRUGS;

EID: 84879719261     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2318     Document Type: Conference Paper

References (164)

1. Allen RP, McCann UD, Recourse GA,. 1993. Persistent effects of (+/-)3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") on human sleep. Sleep 16: 560-564.
2. Back-Madruga C, Boone KB, Chang L, et al,. 2003. Neuropsychological effects of 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) in recreational users. Clin Neuropsychol 17: 446-459.
3. Bedi G, de Wit H,. 2011. Individual differences in acute responses to MDMA in humans: effects of sex and past ecstasy use. Open Addict Jour 4: 6-7.
4. Bedi G, Hyman D, de Wit H,. 2010. Is ecstasy an empathogen? Effects of 3,4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in others. Biol Psychiat 68: 1134-1140.
5. Benningfield MM, Cowan RL,. 2013. Brian serotonin function in MDMA (Ecstasy) users: evidence for persisting neurotoxicity. Neuropsychopharmacology 38: 253-255
6. Berger UV, Gu XF, Azmitia EC,. 1992. The substituted amphetamines 3,4 methylenedioxymethamphetamine, methamphetamine, para-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine. Eur Jour Pharmacol 215: 153-160.
7. Biezonski DK, Meyer JS,. 2011. The nature of 3, 4- methylenedioxymethamphetamine (MDMA)-induced serotonergic dysfunction: evidence for and against the neurodegeneration hypothesis. Curr Neuropharmacol 9: 84-90.
8. Bolla KI, McCann UD, Ricaurte GA,. 1998. Memory impairment in abstinent MDMA ("Ecstasy") users. Neurology 51: 1532-1537.
9. Brière FN, Fallu JS, Janosz M, Pagani LS,. 2012. Prospective associations between meth/amphetamine (speed) and MDMA (Ecstasy) use and depressive symptoms in secondary school students. Jour Epidemiol Community Health 66: 990-994.
10. Burgess AP, Venables L, Jones H, Edwards R, Parrott AC,. 2011. Event related potential (ERP) evidence for selective impairment of verbal recollection in abstinent recreational methylenedioxymethamphetamine ("Ecstasy")/ polydrug users. Psychopharmacology 216: 545-556.
11. Cadet JL, Krasnova IN, Jayanthi S, Lyles J,. 2007. Neurotoxicity of substituted amphetamines: molecular and cellular mechanisms. Neurotox Res 11: 183-202.
12. Cami J, Farré M, Mas M, et al,. 2000. Human pharmacology of 3,4-methylenedioxymethamphetamine ("ecstasy"): psychomotor performance and subjective effects. Jour Clin Psychopharmacol 20: 455-466.
13. Cohen RS,. 1998. The Love Drug: Marching to the Beat of Ecstasy. Haworth Medical Press: New York State.
14. Cole JC, Bailey M, Sumnall HR, Wagstaff GF, King LA,. 2002. The contents of ecstasy tablets: implications for the study of their long-term effects. Addiction 97: 1531-1536.
15. Cowan RL,. 2007. Neuroimaging research in human MDMA users: a review. Psychopharmacology 189: 539-556.
16. Cowan RL, deB Frederick B, Haga E, et al,. 2001. Visual cortex activation using the fMRI BOLD method in human MDMA (ecstasy) users. In: MDMA/Ecstasy Research: Advances, Challenges, and Future Directions. NIDA Conference, Bethesda, MD, USA, July 2001, Conference Abstract, p. 46.
17. Curran HV, Travill RA,. 1997. Mood and cognitive effects of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"): weekend "high" followed by mid-week "low". Addiction 92: 821-831.
18. Dastrup E, Lees MN, Bechara A, Dawson JD, Rizzo M,. 2010. Risky car following in abstinent users of MDMA. Accid Anal Prevent 42: 867-873.
19. Daumann J, Fischermann T, Heekeren K, Henke K, Thron A, Gouzoulis-Mayfrank E,. 2005. Memory-related hippocampal dysfunction in poly-drug ecstasy (3,4-methylenedioxymethamphetamine) users. Psychopharmacology 180: 607-611.
20. Davison D, Parrott AC,. 1997. Ecstasy in recreational users: self-reported psychological and physiological effects. Hum Psychopharmacol 12: 91-97.
21. Degenhardt L, Hall W,. 2009. The health and psychological effects of "ecstasy" (MDMA) use. NDARC monograph, no. 62, University of New South Wales, Australia.
22. Di Iorio CR, Watkins TJ, Dietrich MS, et al,. 2012. Evidence for chronically altered serotonin function in the cerebral cortex of female 3,4-methylenedioxymethamphetamine polydrug users. Arch Gen Psychiatry 69: 399-409.
23. Dickson C, Bruno R, Brown J,. 2009. Investigating the role of serotonin in visual orientation processing using an 'ecstasy' (MDMA)-based research model. Neuropsychobiology 60: 204-212.
24. Doblin R,. 2002. A clinical plan for MDMA (Ecstasy) in the treatment of posttraumatic stress disorder (PTSD): partnering with the FDA. Jour Psychoact Drugs 34: 185-194.
25. Doblin R,. 2011. The use of MDMA for psychotherapy. Breaking Convention Conference, Kent University, UK, April 2011.
26. Dumont GJ, Verkes RJ,. 2006. A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteers. Jour Psychopharmacol 20: 176-187.
27. EMCDDA. 2010. The European Monitoring Centre for Drugs and Drug Addiction annual report 2010: state of the drugs problem in Europe. Europ Surveill, vol 15.
28. Erritzoe D, Frokjaer VG, Holst KK, et al,. 2011. In vivo imaging of cerebral serotonin transporter and serotonin (2A) receptor binding in 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy") and hallucinogen users. Arch Gen Psychiat 68: 562-576.
29. Fisk JE, Montgomery C, Wareing, Murphy PN,. 2005. Reasoning deficits in Ecstasy (MDMA) polydrug users. Psychopharmacology 181: 550-559.
30. Fox H, Parrott AC, Turner JJD,. 2001. Ecstasy/MDMA related cognitive deficits: a function of dosage rather than awareness of problems. Jour Psychopharmacol 15: 273-281.
31. Fox HC, McLean A, Turner JJD, Parrott AC, Rogers R, Sahakian BJ,. 2002. Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA ("ecstasy") polydrug users. Psychopharmacology 162: 203-214.
32. Freedman RR, Johanson CE, Tancer ME,. 2005. Thermoregulatory effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology 183: 248-256.
33. Gerra G, Bassignana S, Zaimovic A, et al,. 2003. Hypothalamic-pituitary- adrenal axis responses to stress in subjects with 3,4- methylenedioxymethamphetamine ('ecstasy') use high correlation with dopamine receptor sensitivity. Psychiat Res 30: 115-124.
34. Gerra G, Kaimovic A, Guicastro G, et al,. 1998. Serotonergic function after 3,4-methylenedioxymethamphetamine. Internat Clin Psychopharmacol 13: 1-9.
35. Green AR, Cross AJ, Goodwin GM,. 1995. Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or ecstasy). Psychopharmacology 119: 247-260.
36. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI,. 2003. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol Revs 55: 463-508.
37. Green AR, King MV, Shortall SE, Fone KCF,. 2012. Lost in translation: preclinical studies on 3,4-methylenedioxymethamphetamine provide information on mechanisms of action, but do not allow accurate prediction of adverse events in humans. Brit Jour Pharmacol 166: 1523-1526.
38. Greene SL, Wood DM, Dargan PI,. 2009. Epidemiological and clinical characteristics of acute MDMA related presentations to an inner city London Emergency Department. Neuropsychobiology 60: 214.
39. Greer G, Tolbert R,. 1986. Subjective reports of the effects of MDMA in a clinical setting. Jour Psychoact Drugs 18: 319-327.
40. Hadjiefthyvoulou F, Fisk JE, Montgomery C, Bridges N,. 2011a. Everyday and prospective memory deficits in ecstasy/polydrug users. J Psychopharmacol 25: 453-464.
41. Hadjiefthyvoulou F, Fisk JE, Montgomery C, Bridges N,. 2011b. Prospective memory functioning among ecstasy/polydrug users: evidence from the Cambridge Prospective Memory Test (CAMPROMPT). Psychopharmacology 215: 761-774.
42. Hall AP, Henry JA,. 2006. Acute toxic effects of 'Ecstasy' (MDMA) and related compounds: overview of pathophysiology and clinical management. Brit Jour Anaesth 96: 678-685.
43. Halpern JH, Pope HG, Sherwood AR, Barry S, Hudson JI, Yurgelun-Todd D,. 2004. Residual effects of illicit 3,4-methylenedioxymethamphetamine in individuals with minimal exposure to other drugs. Drug Alcohol Depend 75: 135-147.
44. Halpern JH, Sherwood AR, Hudson JI, Gruber S, Kozin D, Pope HG,. 2011. Residual features of long term ecstasy use with minimal exposure to other drugs. Addiction 106: 777-786.
45. Hammersley R, Ditton J, Smith I, Short E,. 1999. Patterns of ecstasy use by drug users. Brit Jour Criminol 39: 625-647
46. Harris DS, Baggott M, Mendelson JH, Mendelson JE, Jones RT,. 2002. Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology 162: 396-405.
47. Heffernan TM, Jarvis H, Rodgers J, Scholey AB, Ling J,. 2001. Prospective memory, everyday cognitive failures, and central executive function in recreational users of ecstasy. Hum Psychopharmacol 16: 607-612.
48. Hegadoren KM, Baker GB, Bourin M,. 1998. 3,4-Methylenedioxy analogues of amphetamine: defining the risks to humans. Neurosci Biobehav Revs 23: 539-553.
49. Henry JA, Jeffries KJ, Dawling S,. 1992. Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("Ecstasy"). Lancet 340: 384-387.
50. Hopper JW, Su Z, Looby AR, et al,. 2006. Incidence and patterns of polydrug use and craving for ecstasy in regular ecstasy users: an ecological momentary assessment study. Drug Alcohol Depend 85: 221-235.
51. Huether G, Zhou D, Ryuther E,. 1997. Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4 methylenedioxymethamphetamine (MDMA, "'ecstasy"') and its congeners. Jour Neural Transmiss 104: 771-794.
52. Jacobsen LK, Mencl WE, Pugh KR, Skudlarski P, Krystal JH,. 2004. Preliminary evidence of hippocampal dysfunction in adolescent MDMA ("ecstasy") users: possible relationship to neurotoxic effects. Psychopharmacology 173: 383-390.
53. Jansen KLR,. 1999. Ecstasy (MDMA) dependence. Drug Alcohol Depend 53: 121-124.
54. Jones KA, Callan F, Blagrove MT, Parrott AC,. 2008. Sleep, energy and self-rated cognition across 7 nights following recreational ecstasy/MDMA use. Sleep and Hypnosis 10: 16-28.
55. Kalant H,. 2001. The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs. Canad Med Assn Jour 165: 17-28.
56. Karageorgiou J, Dietrich MS, Charboneau EJ, et al,. 2009. Prior MDMA (Ecstasy) use is associated with increased basal ganglia-thalamocortical circuit activation during motor task performance in humans: an fMRI study. Neuroimage 46: 817-826.
57. Kirkpatrick MG, Gunderson EW, Perez AY, Haney M, Foltin RW, Hart CL,. 2012. A direct comparison of the behavioral and physiological effects of methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology 219: 109-22.
58. Kish SJ, Lerch J, Furukawa Y, et al,. 2010. Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[(11)C]DASB and structural brain imaging study. Brain 133: 1779-1797.
59. Kopelman MD, Reed LJ, Marsden P, et al,. 2001. Amnesic syndrome and severe ataxia following the recreational use of 3,4- methylenedioxymethamphetamine (MDMA, 'Ecstasy') and other substances. Neurocase 7: 423-432.
60. Krul J, Girbes AR, Sanou BT,. 2012. Increase in serious ecstasy-related incidents in the Netherlands. Lancet 380: 1385.
61. Krystal JH, Price LH, Opsahl C, Ricaurte GA, Heninger GR,. 1992. Chronic 3,4-methylenedioxymethamphetamine (MDMA) use: effects on mood and neuropsychological function? Amer Jour Drug Alcohol Abuse 18: 331-341.
62. Laws KR, Kokkalis J,. 2007. Ecstasy (MDMA) and memory function: a meta-analytic update. Hum Psychopharmacol 22: 381-388.
63. Liechti ME, Gamma A, Vollenweider FX,. 2001. Gender differences in the subjective effects of MDMA. Psychopharmacology 154: 161-168.
64. MacInnes N, Handley SL, Harding GF,. 2001. Former chronic methylenedioxymethamphetamine (MDMA or ecstasy) users report mild depressive symptoms. Jour Psychopharmacol 15: 181-186.
65. McCann UD, Slate SO, Ricaurte GA,. 1996. Adverse reactions with 3,4-methelenedioxymethamphetamine (MDMA: 'ecstasy'). Drug Saf 15: 107-115.
66. McCann UD, Szabo Z, Vranesic M, et al,. 2008. Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (+/-)3,4-methylenedioxymethamphetamine ("ecstasy") users: relationship to cognitive performance. Psychopharmacology 200: 439-450.
67. McCann UD, Ricaurte GA,. 1991. Lasting neuropsychiatric sequelae of (+/-) methylenedioxymethamphetamine ('Ecstasy') in recreational users. Jour Clin Psychopharmacol 11: 302-305.
68. McCann UD, Ricaurte GA,. 2007. Effects of (+/-) 3,4- methylenedioxymethamphetamine (MDMA) on sleep and circadian rhythms. Scient World Jour 2: 231-238.
69. McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA,. 1998. Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurones in human beings. Lancet 352: 1433-1437.
70. McCann UD, Mertl M, Eligulashvili V, Ricaurte GA,. 1999. Cognitive performance in (+/-)3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") users: a controlled study. Psychopharmacology 143: 417-425.
71. McCann UD, Sgambati FP, Schwartz AR, Ricaurte GA,. 2009. Sleep apnea in young abstinent recreational MDMA ("ecstasy") consumers. Neurology 73: 2011-2017.
72. McDowell DM, Kleber HD,. 1994. MDMA: its history and pharmacology. Psychiat Annals 24: 127-130.
73. McElhatton PR, Bateman DN, Evans C, Pughe KR, Thomas SH,. 1999. Congenital anomalies after prenatal ecstasy exposure. Lancet 354: 1441-1442.
74. Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Doblin R,. 2011. The safety and efficacy of +/-3,4-methylenedioxymethamphetamine assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. Jour Psychopharmacol 25: 439-452.
75. Montgomery C, Hatton NP, Fisk JE, Ogden RS, Jansari A,. 2010. Assessing the functional significance of ecstasy-related memory deficits using a virtual reality paradigm. Hum Psychopharmacol 25: 318-325.
76. Montiel-Duarte C, Varela-Rey M, Oses-Prieto JA, et al,. 2002. 3,4-Methylenedioxymethamphetamine ("Ecstasy") induces apoptosis of cultured rat liver cells. Biochim Biophys Acta 1588: 26-32.
77. Morefield KM, Keane M, Felgate P, White JM, Irvine RJ,. 2009. The acute psychobiological impacts of illicit 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') consumption in recreational environments. Neuropsychobiology 60: 216-217.
78. Morgan MJ,. 1999. Memory deficits associated with recreational use of "ecstasy" (MDMA). Psychopharmacology 141: 30-36.
79. Morgan MJ,. 2000. Ecstasy (MDMA): a review of its possible persistent psychological effects. Psychopharmacology 152: 230-248
80. Morgan MJ, McFie L, Fleetwood LH, Robinson JA,. 2002. Ecstasy (MDMA): are the psychological problems associated with its use reversed by prolonged abstinence? Psychopharmacology 159: 294-303.
81. Murphy PN, Wareing M, Fisk JE, Montgomery C,. 2009. Executive working memory deficits in abstinent ecstasy/MDMA users: a critical review. Neuropsychobiology 60: 159-175.
82. Murphy PN, Bruno R, Ryland L, et al,. 2012. The effects of 'ecstasy' (MDMA) on visuospatial memory performance: findings from a systematic review with meta-analyses. Hum Psychopharmacol 27: 113-138.
83. Nichols DE,. 1986. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J Psychoact Drugs 18: 305-313.
84. Nutt D, King la, Saulsbury W, Blakemore C,. 2007. Development of a rational scale to assess the harm of drugs of potential misuse. Lancet 369: 1047-1053.
85. Parrott AC,. 2000. Human research on MDMA (3,4- methylenedioxymethamphetamine) neurotoxicity: cognitive and behavioural indices of change. Neuropsychobiology 42: 17-24.
86. Parrott AC,. 2001. Human psychopharmacology of Ecstasy (MDMA): a review of fifteen years of empirical research. Hum Psychopharmacol 16: 557-577.
87. Parrott AC,. 2002. Recreational Ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol Biochem Behav 71: 837-844
88. Parrott AC,. 2004a. Is Ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, dosage levels, and the changing perceptions of purity. Psychopharmacology 173: 234-241.
89. Parrott AC,. 2004b. MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy: the neuropsychobiological implications of taking it at dances and raves. Neuropsychobiology 50: 329-335.
90. Parrott AC,. 2005. Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy. Jour Psychopharmacol 19: 71-83.
91. Parrott AC,. 2006. MDMA in humans: factors which affect the neuropsychobiological profiles of recreational Ecstasy users, the integrative role of bio-energetic stress. Jour Psychopharmacol 20: 147-163.
92. Parrott AC,. 2007a. The psychotherapeutic potential of MDMA (3,4-methylenedioxymethamphetamine): an evidence-based review. Psychopharmacology 191: 181-193.
93. Parrott AC,. 2007b. How harmful is Ecstasy/MDMA: a empirical evaluation using the 'Lancet' scale for drug-related harm. Jour Psychopharmacol 23: a41.
94. Parrott AC,. 2008. Drug taking-for better or for worse? Psychologist 21: 924-927.
95. Parrott AC,. 2009. Cortisol and MDMA (3,4-methylenedioxymethamphetamine): neurohormonal aspects of bioenergetic-stress in Ecstasy users. Neuropsychobiology 60: 148-158.
96. Parrott AC,. 2010. Conscious awareness versus optimistic beliefs in recreational Ecstasy/MDMA users. In New Horizons in the Neuroscience of Consciousness, Perry E, Collerton D, LeBeau F, Ashton HE, (eds). John Benjamins Publishers: Amsterdam.
97. Parrott AC,. 2011. Residual neurocognitive features of Ecstasy use: a reinterpretation of Halpern et al. (2011) consistent with serotonergic neurotoxicity. Addiction 106: 1365-1368.
98. Parrott AC,. 2012a. MDMA and temperature: a review of the thermal effects of 'Ecstasy' in humans. Drug Alcohol Depend 121: 1-9.
99. Parrott AC,. 2012b. MDMA and 5-HT neurotoxicity: the empirical evidence for its adverse effects in humans-no need for translation. Brit Jour Pharmacol 166: 1518-1520.
100. Parrott AC,. 2013. MDMA, serotonergic neurotoxicity, and the diverse functional deficits of recreational Ecstasy users. Neurosci Biobehav Revs (in press).
101. Parrott AC, Lasky J,. 1998. Ecstasy (MDMA) effects upon mood and cognition; before, during, and after a Saturday night dance. Psychopharmacology 139: 261-268.
102. Parrott AC, Lees A, Garnham NJ, Jones M, Wesnes K,. 1998. Cognitive performance in recreational users of MDMA or "ecstasy": evidence for memory deficits. Jour Psychopharmacol 12: 79-83.
103. Parrott AC, Sisk E, Turner J,. 2000. Psychobiological problems in heavy 'ecstasy' (MDMA) polydrug users. Drug Alc Depend 60: 105-110.
104. Parrott AC, Milani RM, Gouzoulis-Mayfrank E, Daumann J,. 2007. Cannabis and Ecstasy/MDMA (3,4-methylenedioxymethamphetamine): an analysis of their neuropsychobiological interactions in recreational users. J Neural Transm 114: 959-968.
105. Parrott AC, Milani RM, Parmar R, Turner JJD,. 2001. Recreational Ecstasy/MDMA and other drug users form the UK and Italy: psychiatric symptoms and psychobiological problems. Psychopharmacology 159: 77-82.
106. Parrott A, Morinan A, Moss M, Scholey A,. 2004. Understanding Drugs and Behaviour. Wiley: Chichester.
107. Parrott AC, Rodgers J, Buchanan T, Ling J, Heffernan T, Scholey AB,. 2006. Dancing hot on ecstasy: physical activity and thermal comfort ratings are associated with the memory and other psychobiological problems of recreational MDMA users. Hum Psychopharmacol 21: 285-298.
108. Parrott AC, Lock J, Conner AC, Kissling C, Thome J,. 2008. Dance clubbing on MDMA and during abstinence from Ecstasy/MDMA: prospective neuroendocrine and psychobiological changes. Neuropsychobiology 57: 165-180.
109. Parrott AC, Gibbs A, Scholey AB, et al,. 2011a. MDMA and methamphetamine: some paradoxical negative and positive mood changes in an acute dose laboratory study. Psychopharmacology 215: 527-536.
110. Parrott AC, Evans LJ, Howells J, Robart R,. 2011b. Cocaine versus Ecstasy/MDMA: comparative effects on mood and cognition in recreational users. Open Addiction Journal 4: 36-37.
111. Parrott AC, Jones L, Sands HR, et al,. 2012. High cortisol levels in recent Ecstasy/MDMA users: preliminary findings from the Swansea, Westminster and Dresden collaborative study. Psychobiology Section of the British Psychological Society Annual Scientific Meeting, Conference Abstract, p. 14.
112. Peroutka SJ,. 1989. 'Ecstasy': a human neurotoxin? Arch Gen Psychiat 46: 191.
113. Peroutka SJ, Newman H, Harris H,. 1988. Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology 1, 273-277.
114. Puerta E, Hervias I, Aguirre N,. 2009. On the mechanisms underlying 3,4-methylenedioxymethamphetamine toxicity: the dilemma of the chicken and the egg. Neuropsychobiology 60: 119-129.
115. Quednow BB, Kuhn KU, Hoenig K, Maier W, Wagner M,. 2004. Prepulse inhibition and habituation of acoustic startle response in male MDMA ('Ecstasy') users, cannabis users, and healthy controls. Neuropsychopharmacology 29: 982-990.
116. Reay JL, Hamilton C, Kennedy DO, Scholey AB,. 2006. MDMA polydrug users show process-specific central executive impairments coupled with impaired social and emotional judgement processes. Jour Psychopharmacol 20: 385-388.
117. Rendell PG, Gray TJ, Henry JD, Tolan A,. 2007. Prospective memory impairment in "ecstasy" (MDMA) users. Psychopharmacology 194: 497-504.
118. Reneman L, de Win MM, van den Brink W, Booij J, den Heeten GJ,. 2006. Neuroimaging findings with MDMA/ecstasy: technical aspects, conceptual issues and future prospects. Jour Psychopharmacol 20: 164-175.
119. Renfroe CL,. 1986. MDMA on the street: analysis anonymous. Jour Psychoact Drugs 18: 363-369.
120. Riahi S, Eynollahi S, Ganjali MR,. 2010. Computational studies on effects of MDMA as an anticancer drug on DNA. Chem Biol Drug Des 76: 425-432.
121. Ricaurte GA, Yuan J, McCann UD,. 2000. (+/-)3,4- methylenedioxymethamphetamine (MDMA, "ecstasy")-induced serotonin neurotoxicity: studies in animals. Neuropsychobiology 42: 5-10
122. Rizzo M, Lamers CTJ, Sauer CG, Ramaekers JG, Bechara A, Anderson GJ,. 2005. Impaired perception of self-motion (heading) in abstinent ecstasy and marijuana users. Psychopharmacology 179: 559-566.
123. Roberts GM, Nestor L, Garavan H,. 2009. Learning and memory deficits in ecstasy users and their neural correlates during a face-learning task. Brain Res 1292: 71-81.
124. Rodgers J,. 2000. Cognitive performance amongst recreational users of "ecstasy". Psychopharmacology 151: 19-24.
125. Rodgers J, Buchanan T, Scholey AB, Heffernan TM, Ling J, Parrott AC,. 2003. Patterns of drug use and the influence of gender on self reports of memory ability in ecstasy users: a Web based study. Jour Psychopharmacol 17: 379-386.
126. Rogers G, Elston J, Garside R, et al,. 2009. The harmful health effects of recreational ecstasy: a systematic review of observational evidence. Health Technol Assess 13: 1-315.
127. Roiser JP, Sahakian BJ,. 2004. Relationship between ecstasy use and depression: a study controlling for poly-drug use. Psychopharmacology 173: 411-417.
128. Rosenson J, Smollin C, Sporer KA, Blanc P, Olson KR,. 2007. Patterns of ecstasy-associated hyponatremia in California. Ann Emerg Med 49: 164-171.
129. Saunders N,. 1997. Ecstasy Reconsidered. Turnaround: London.
130. Schifano F,. 2000. Potential human neurotoxicity of MDMA ('ecstasy'): subjective self-reports, evidence from an Italian drug addiction centre and clinical case studies. Neuropsychobiology 42: 25-33.
131. Schifano F, Magni G,. 1994. MDMA ('ecstasy') abuse: psychopathological features and craving for chocolate: a case series. Biol Psychiat 36: 763-767.
132. Schifano F, Di Furia L, Forza G, Minicuci N, Bricolo R,. 1998. MDMA ('ecstasy') consumption in the context of polydrug abuse: a report on 150 patients. Drug Alcohol Depend 52: 85-90.
133. Schifano F, Oyefeso A, Webb L, Pollard M, Corkery J, Ghodse AH,. 2003. Review of deaths related to taking ecstasy, England and Wales, 1997-2000. Brit Med Jour 326: 8-81.
134. Schifano F, Corkery J, Naidoo V, Oyefeso A, Ghodse AH,. 2010. Overview of amphetamine-type stimulant mortality data UK, 1997-2007. Neuropsychobiology 61: 122-130.
135. Scholey AB, Parrott AC, Buchanan T, Heffernan T, Ling J, Rodgers J,. 2004. Increased intensity of Ecstasy and polydrug usage in the more experienced recreational Ecstasy/MDMA users: a www study. Addictive Behav 29: 743-752.
136. Scholey AB, Owen L, Gates J, et al,. 2011. Hair MDMA samples are consistent with reported Ecstasy use: findings from an Internet study investigating effects of Ecstasy on mood and memory. Neuropsychobiology 63: 15-21.
137. Shulgin AT,. 1986. The background and chemistry of MDMA. Jour Psychoact Drugs 18: 291-304.
138. Simantov R,. 2004. Multiple molecular and neuropharmacological effects of MDMA (Ecstasy). Life Sci 74: 803-814.
139. Singer LT, Linares TJ, Ntiri S, Henry R, Minnes S,. 2004. Psychosocial profiles of older adolescent MDMA users. Drug Alcohol Depend 74: 245-252.
140. Singer LT, Moore DG, Fulton S, et al,. 2012a. Neurobehavioral outcomes of infants exposed to MDMA (Ecstasy) and other recreational drugs during pregnancy. Neurotoxicol Teratol 34: 303-310.
141. Singer LT, Moore DG, Min MO, et al,. 2012b. One-year outcomes of prenatal exposure to MDMA and other recreational drugs. Pediatrics 130: 407-413.
142. Smith ID, Simpson KJ, Garden OJ, Wigmore SJ,. 2005. Non-paracetamol drug-induced fulminant hepatic failure among adults in Scotland. Eur Jour Gastroenterol Hepatol 17: 161-167.
143. Soar K, Turner JJD, Parrott AC,. 2001. Psychiatric disorders in Ecstasy (MDMA) users: a literature review focusing upon personal predispositions and drug histories. Hum Psychopharmacol 16: 641-645.
144. Soar K, Mason C, Potton A, Dawkins L,. 2012. Neuropsychological effects associated with recreational cocaine use. Psychopharmacology 222: 633-643.
145. Solowij N, Hall W, Lee N,. 1992. Recreational MDMA use in Sydney: a profile of ecstasy users and their experiences with the drug. Brit Jour Addict 87: 1161-1172.
146. Spruit IP,. 2001. Monitoring synthetic drug markets, trends and public health. Subst Use Misuse 36: 23-47.
147. Steele TD, McCann UD, Ricaurte GA,. 1994. 3,4- Methylenedioxymethamphetamine (MDMA, "ecstasy"): pharmacology and toxicology in animals and humans. Addiction 89: 539-551.
148. Stough C, Downey LA, King R, Papafotiou K, Swann P, Ogden E,. 2012. The acute effects of 3,4-methylenedioxymethamphetamine and methamphetamine on driving: a simulator study. Accid Anal Prev 45: 493-497.
149. Suy K, Gijsenbergh F, Baute L,. 1999. Emergency medical assistance during a mass gathering. Eur Jour Emerg Med 6: 249-254.
150. Tancer M, Johanson CE,. 2007. The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology 189: 565-573.
151. Topp L, Hando J, Dillon P, Roche A, Solowij N,. 1999. Ecstasy use in Australia: patterns of use and associated harm. Drug Alcohol Depend 55: 105-115.
152. Van Dijken GD, Blom RE, Hene RJ, Boer WH,. 2013. High incidence of mild hyponatraemia in females using ecstasy at a rave party. Nephrol Dial Transplant [March 8 epub].
153. Verheyden SL, Maidment R, Curran HV,. 2003. Quitting ecstasy: an investigation of why people stop taking the drug and their subsequent mental health. Jour Psychopharmacol 17: 371-378.
154. Verkes RJ, Gigsman HJ, Pieters MSM, Schoemaker RC, de Visser S, Kuijpers M,. 2001. Cognitive performance and serotonergic function in users of Ecstasy. Psychopharmacology 53: 196-202.
155. Vogels N, Brunt TM, Rigter S, van Dijk P, Vervaeke H, Niesink RJ,. 2009. Contents of ecstasy in the Netherlands: 1993-2008. Addiction 104: 2057-2066.
156. Vollenweider FX, Gamma A, Liechti M, Huber T,. 1998. Psychological and cardiovascular effects and short-term sequelae of MDMA ("Ecstasy") in MDMA-naive healthy humans. Neuropsychopharmacology 19: 241-251.
157. Wasik AM, Gandy MN, Mclldowie M, et al,. 2011. Enhancing the anti-lymphoma potential of 3,4-methylenedioxymethamphetamine ('ecstasy') through iterative chemical redesign: mechanisms and pathways to cell death. Invest New Drugs 30: 1471-1483.
158. Webb E, Ashton CH, Kelly P, Kamali F,. 1996. Alcohol and drug use in UK university students. Lancet 348: 922-925.
159. Williamson S, Gossop M, Powis B, Griffiths P, Fountain J, Strang J,. 1997. Adverse effects of stimulant drugs in a community sample of drug users. Drug Alc Depend 44: 87-94.
160. Winstock AR,. 1991. Chronic paranoid psychosis after misuse of MDMA. Brit Med Jour 302: 1150-1151.
161. Winstock AR, Griffiths P, Stewart D,. 2001. Drugs and the dance music scene: a survey of current drug use patterns among a sample of dance music enthusiasts in the UK. Drug Alcohol Depend 64: 9-17.
162. Zakzanis KK, Campbell Z,. 2006. Memory impairment in now abstinent MDMA users and continued users: a longitudinal follow-up. Neurology 66: 740-741.
163. Zakzanis KK, Young DA,. 2001. Memory impairment in abstinent MDMA ("ecstasy") users: a longitudinal investigation. Neurology 56: 966-969.
164. Zhou JF, Chen P, Zhou YH, Zhang L, Chen HH,. 2003. 3,4- Methylenedioxymethamphetamine abuse may cause oxidative stress and potential free radical damage. Free Radical Res 37: 491-497.